Mounjaro is an MHRA-approved, prescription treatment designed to assist with weight loss for adults aged 18 and over. Originally approved for type 2 diabetes, Mounjaro is now recognised as a powerful aid for weight management, especially when combined with a calorie-reduced diet and regular exercise. To start your weight loss journey today, use the button below to start an online consultation.
Mounjaro is best suited for adults with a Body Mass Index (BMI) of 30 or higher, or those with a BMI between 27 and 30 who also suffer from weight-related health conditions like prediabetes or high blood pressure. However, it’s crucial to consult your doctor before starting Mounjaro—especially if you have existing health issues or are taking other medications.
Only some people are candidates for weight loss medications. You should not use Mounjaro if you are allergic to any of the injection ingredients, especially tirzepatide. It is also unsuitable for people under 18.
If you are pregnant or breastfeeding, Mounjaro is not recommended.
If you are being treated for diabetes, you should speak to your doctor about using Mounjaro as it can cause low blood sugar when used with other medicines for type 2 diabetes, such as insulin.
Speak to your doctor before using Mounjaro if you have:
an existing health condition that affects the emptying of your stomach, such as severe gastroparesis
an eye condition, such as diabetic retinopathy
ever had pancreatitis, which is an inflammation of the pancreas
Mounjaro may interact with other medications, so consult your doctor if you take any prescription, over-the-counter drugs or herbal remedies.
Medications are most effective with lifestyle changes, such as a balanced diet and regular exercise. They are not a substitute for healthy living. For more information, read the patient brochure.
Mounjaro comes in an easy-to-use pre-filled injection pen containing various doses of the active ingredient, tirzepatide. Doses of 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg are available.
It is injected under the skin of your stomach area, thigh, or upper arm.
Starting at a dosage of 2.5mg once a week allows you to adapt to the treatment gradually. After 4 weeks, the dose can be increased to 5 mg once weekly. If needed, dose increases can be made in 2.5 mg increments after a minimum of 4 weeks on the current dose. Depending on how you respond to the treatment, the recommended maintenance doses are 5mg, 10mg or 15 mg once weekly. The maximum dose is 15 mg once weekly.
Mounjaro has shown impressive results in clinical trials. People who took Mounjaro (tirzepatide) weekly at a dose of 5 mg lost an average of 16.1 kg (35.5 lb) after 72 weeks. Those taking the 10 mg dose lost an average of 22.2 kg (48.9 lb). Participants on the 15 mg dose lost an average of 23.6 kg (52.0 lb) over the same time period. In comparison, those who received a placebo only lost an average of 2.4 kg (5.3 lb) in 72 weeks.
Don’t hesitate to take control of your weight loss journey. Start with Mounjaro today—start an online consultation and discover how this innovative treatment can support your goals.
Mounjaro is best suited for adults with a Body Mass Index (BMI) of 30 or higher, or those with a BMI between 27 and 30 who also suffer from weight-related health conditions like prediabetes or high blood pressure. However, it’s crucial to consult your doctor before starting Mounjaro—especially if you have existing health issues or are taking other medications.
Only some people are candidates for weight loss medications. You should not use Mounjaro if you are allergic to any of the injection ingredients, especially tirzepatide. It is also unsuitable for people under 18.
If you are pregnant or breastfeeding, Mounjaro is not recommended.
If you are being treated for diabetes, you should speak to your doctor about using Mounjaro as it can cause low blood sugar when used with other medicines for type 2 diabetes, such as insulin.
Speak to your doctor before using Mounjaro if you have:
an existing health condition that affects the emptying of your stomach, such as severe gastroparesis
an eye condition, such as diabetic retinopathy
ever had pancreatitis, which is an inflammation of the pancreas
Mounjaro may interact with other medications, so consult your doctor if you take any prescription, over-the-counter drugs or herbal remedies.
Medications are most effective with lifestyle changes, such as a balanced diet and regular exercise. They are not a substitute for healthy living. For more information, read the patient brochure.
| Mounjaro | Wegovy | |
|---|---|---|
| Weight Loss Achievable | Up to 22.5% | Up to 17.4% |
| Also prevents against heart disease? | No | Yes |
| Also treats type 2 diabetes? | Yes | No |
| Suitable for use with oral contraception pill? | No | Yes |
| Dosage | Once weekly | Once weekly |
| Dose flexibility | Increase, decrease or maintain monthly | Increase, decrease or maintain monthly |
| Active ingredient | Tirzepatide | Semaglutide |
| Starting dose | 2.5mg | 0.25mg |
| Dose strength 2 | 5mg | 0.5mg |
| Dose strength 3 | 7.5mg | 1mg |
| Dose strength 4 | 10mg | 1.7mg |
| Dose strength 5 | 12.5mg | 2.4mg |
| Dose strength 6 | 15mg | 2.4mg |
Mounjaro and Wegovy have shown impressive results for weight loss in clinical trials. Mounjaro users exhibited a substantial weight loss ranging from 21% to 22.5% at its highest dosage—a figure similar to the weight reduction achieved through bariatric surgery. In contrast, using Wegovy resulted in an average weight loss of around 15% in adults. While direct head-to-head comparisons are limited, the research suggests that Mounjaro's highest dose tends to outperform Wegovy regarding weight loss.
Mounjaro UK is currently available only through private prescriptions for weight loss medication, and the price will vary. The clinical provider who prescribes it will determine the cost. It could become available on the NHS as early as March.
With Mounjaro, patients may lose an average of 15-20% of their initial body weight when combined with lifestyle changes. Individual results vary, so consult your healthcare provider for personalised guidance.
Mounjaro is currently used to treat individuals with type 2 diabetes, which is characterised by elevated blood sugar levels. It will soon be available for doctors and GPs in the UK to prescribe for patients requiring clinical support with weight loss and management.
Mounjaro is the first approved medication that imitates glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Existing approved weight loss injections only imitate GLP-1.
By emulating the functions of these two hormones, tirzepatide (the active ingredient) effectively manages appetite by promoting a sense of fullness with smaller food intake, reducing hunger, and curbing food cravings.
The highest maintenance dose of Mounjaro (15mg for 72 weeks) has no clinically known adverse long-term effects.
As Mounjaro has been proven to help people lose up to 22% of their body weight, you’ll likely be removed from treatment once you hit your goal weight. You must only take Mounjaro for as long as your GP prescribes.
Weight gain can occur when you stop taking Mounjaro, so it’s necessary to continue eating healthily and regularly exercising to prevent this from happening.
